R. Abbas

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors

Kwok‐Kin Wong, Paula M. Fracasso, Ronald M. Bukowski et al. · Journal of Clinical Oncology · 2006 · 57 citations

Preliminary Phase 1, Solid Tumors, Pathology +20

Dynamics of glutathione and ophthalmate traced with²H-enriched body water in rats and humans

Rajan S. Kombu, Guofang Zhang, R. Abbas et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009 · 33 citations · Full text

Glutathione Disulfide, Mammalian Physiology, Lipid Peroxidation +17

Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors

Wells A. Messersmith, S Krishnamurthi, Becker Hewes et al. · Journal of Clinical Oncology · 2007 · 30 citations

Bosutinib Exposure, Oncology, Chemoprevention Strategy +15

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival

R. Abbas, Karen McColl, Adam Kresak et al. · Cancer Medicine · 2015 · 28 citations · Full text

Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib

Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2007 · 24 citations

Cytogenetics, Mixed-phenotype Acute Leukemia, Immunology +20